APLS Q4 2022 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$23M-62.4% YoY

Gross Profit

$20M87.1% margin

Operating Income

-$164M-723.9% margin

Net Income

-$166M-732.4% margin

EPS (Diluted)

$-1.50

QoQ Revenue Growth

+2.8%

Cash Flow

Operating Cash Flow

-$141M

Free Cash Flow

-$142M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$760M

Total Liabilities

$590M

Stockholders' Equity

$170M

Cash & Equivalents

$552M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$23M	$60M	-62.4%
Gross Profit	$20M	$60M	-67.0%
Operating Income	-$164M	-$89M	-83.5%
Net Income	-$166M	-$148M	-12.2%

Revenue Segments

Product

$20M87%

Licensing And Other Revenue

$3M13%